Chemocentryx takes a leap of faith with avacopan
Despite the phase II failure, Chemocentryx is pushing on in hidradenitis suppurativa.
Small Galapagos setback prompts a bigger loss of sentiment
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
Clinical setback lays bare Vertex’s weakness
As the company is punished for its failure to diversify, could it be forced into making an acquisition?
Toxicity concerns now hit the Covid antibody approach
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
J&J pause adds to adenovirus vaccine doubts
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Shedding light on Intercept’s opaque disclosure
Intercept’s woes have continued as a possible new liver toxicity signal was buried in a regulatory filing. What could this mean?
